| 0.9998 0.09 (9.89%) | 12-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.33 |
1-year : | 1.55 |
| Resists | First : | 1.13 |
Second : | 1.33 |
| Pivot price | 0.93 |
|||
| Supports | First : | 0.93 |
Second : | 0.8 |
| MAs | MA(5) : | 0.9 |
MA(20) : | 0.93 |
| MA(100) : | 0.99  |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 38.9 |
D(3) : | 29.9 |
| RSI | RSI(14): 55 |
|||
| 52-week | High : | 2.14 | Low : | 0.7 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ DYAI ] has closed below upper band by 18.3%. Bollinger Bands are 22.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.01 - 1.01 | 1.01 - 1.02 |
| Low: | 0.89 - 0.89 | 0.89 - 0.89 |
| Close: | 0.99 - 1 | 1 - 1.01 |
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Tue, 16 Dec 2025
Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Novan (NOVN) and Dyadic International (DYAI) - The Globe and Mail
Tue, 02 Dec 2025
Analysts Offer Insights on Healthcare Companies: Personalis (PSNL), Dyadic International (DYAI) and NeurAxis, Inc. (NRXS) - The Globe and Mail
Wed, 12 Nov 2025
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress - GlobeNewswire
Tue, 11 Nov 2025
Dyadic International Inc (DYAI) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Mon, 10 Nov 2025
Dyadic (DYAI) gains access to ERS’ 100+ CRISPR/Cas9 patents to speed strain engineering - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 36 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 25.1 (%) |
| Held by Institutions | 17 (%) |
| Shares Short | 54 (K) |
| Shares Short P.Month | 91 (K) |
| EPS | -0.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.07 |
| Profit Margin | -219.9 % |
| Operating Margin | -164.3 % |
| Return on Assets (ttm) | -39.8 % |
| Return on Equity (ttm) | -244.2 % |
| Qtrly Rev. Growth | -40.5 % |
| Gross Profit (p.s.) | 0.02 |
| Sales Per Share | 0.09 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -4.55 |
| PEG Ratio | 0 |
| Price to Book value | 14.28 |
| Price to Sales | 10.83 |
| Price to Cash Flow | -7.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|